Triveni Bio Raises $115M Series B Financing to Advance Antibody Treatments for I&I DisordersTriveni Bio Inc. raised $115 million to accelerate its antibody therapies for immune and inflammatory disorders, focusing on novel pathways and advanced treatment efficacy.